DelveInsight’s “Multiple System Atrophy (MSA) Pipeline Insights, 2021” research provides detailed insights into the market’s current clinical development status and growth prospects.
Some of the Key Highlights from the Multiple System Atrophy Pipeline Report
Notable companies like Biohaven Pharmaceutical, Alterity Therapeutics, Stealth BioTherapeutics, AFFiRiS, others are testing their drug candidates for Multiple System Atrophy.
Pipeline therapy for Multiple System Atrophy which is in Phase III of clinical trials include Verdiperstat while pipeline therapy such as ATH 434 is in Phase II clinical trials.
SBT-272, pipeline therapy for Multiple System Atrophy is in the early stage of development i.e. Phase I.
Some Multiple System Atrophy pipeline therapy such as PD04 is still in the preclinical stage of development.
Get more insights @ Multiple System Atrophy Pipeline Insights
Multiple System Atrophy: Disease Overview
Multiple System Atrophy (MSA) is a rare neurological illness characterised by autonomic dysfunction, tremors, sluggish movement, muscle rigidity, postural instability, and ataxia (often referred to as Parkinsonism). This is caused by progressive degeneration of neurons in several areas of the brain, including the basal ganglia, inferior olivary nucleus, and cerebellum.
Multiple System Atrophy: Symptoms
MSA’s initial symptoms are typically difficult to distinguish from those of Parkinson’s disease. It includes:
Slowness of movement, tremor, or rigidity (stiffness)
Clumsiness or incoordination
Impaired speech, a croaky, quivering voice
Fainting or lightheadedness due to orthostatic hypotension, a condition in which blood pressure drops when rising from a seated or lying down position
Bladder control problems, such as a sudden urge to urinate or difficulty emptying the bladder.
Multiple System Atrophy: Treatment
MSA does not have a specific treatment. The goal of treatment is to keep the disease’s symptoms under control. Individuals with MSA may be prescribed drugs that are used to treat Parkinson’s disease, most commonly levodopa (administered in Sinemet tablets).
Get more information about the disease @ Multiple System Atrophy Symptoms, Causes and Diagnosis
Multiple System Atrophy Pipeline Analysis: Drug Profile
Verdiperstat: Biohaven Pharmaceutical
Biohaven is developing Verdiperstat as a potential first-in-class, oral, brain-penetrant, irreversible inhibitor of MPO as a therapy for MSA. Verdiperstat could possibly be used to treat a variety of additional diseases that are linked to oxidative stress, inflammation, and neurodegeneration.
Multiple System Atrophy Pipeline Therapies and Key Companies
Verdiperstat – Biohaven Pharmaceutical
ATH 434: Alterity Therapeutics
SBT-272: Stealth BioTherapeutics
Multiple System Atrophy Therapeutics Assessment
By Product Type
By Route of Administration
By Molecule Type
Stem Cell Therapy
By Mechanism of Action
Multiple Kinase Inhibitors
Scope of the Report
MSA Key Players: Biohaven Pharmaceutical, Alterity Therapeutics, Stealth BioTherapeutics, AFFiRiS, among others
MSA Pipeline Therapies: Verdiperstat, ATH 434, SBT-272, PD04, and others
Table of Contents
Multiple System Atrophy: Overview
Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment
MSA Pipeline Therapeutics
MSA Late Stage Products (Phase III)
MSA Mid Stage Products (Phase II)
MSA Early Stage Products (Phase I)
MSA Preclinical Stage Products
MSA Therapeutic Assessment
MSA Inactive Products
MSA Company-University Collaborations (Licensing/Partnering) Analysis
Multiple System Atrophy Key Companies
Multiple System Atrophy Key Products
Multiple System Atrophy- Unmet Needs
Multiple System Atrophy- Market Drivers and Barriers
Multiple System Atrophy- Future Perspectives and Conclusion
Multiple System Atrophy Analyst Views
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Key questions answered in the Multiple System Atrophy Pipeline Report
What are the options for treating Multiple System Atrophy?
How many firms are working on remedies for Multiple System Atrophy?
Which of these firms’ therapies are the most popular?
What is the total number of Multiple System Atrophy therapies produced by each company?
How many novel therapies are being developed for Multiple System Atrophy in the early, mid, and late stages?
How many of the medications in development can be used on their own or in conjunction with other therapies?
What are the most significant industry-industry and industry-academy cooperation, mergers and acquisitions, and licensure practises that will have an impact on Multiple System Atrophy?
Central Nervous System Lymphoma Pipeline Insights
Get comprehensive analysis of Central Nervous System Lymphoma pipeline therapies and key companies including Shandong New Time Pharmaceutical, AstraZeneca, Bristol-Myers Squibb, Janseen, Celgene, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States